Key Stats for CVS Stock
- This week’s performance: -1.5%
- 52-week range: $70 to $111
- Valuation model target price: $107
- Implied upside: 12.9% over 2.3 years
Uncover what CVS’s 2027 headwinds mean for your price target (It’s free) >>>
A Great Quarter, A Cloudy 2027: CVS’s Turnaround Hits Turbulence
CVS Health (CVS) closed at $95 this week, down slightly, after posting one of its strongest quarters in years. Q2 revenue rose 7.3% to $106 billion, and adjusted EPS jumped 42% to $2.58, beating estimates by a wide margin. Management raised full-year guidance to $7.90 to $8.10 per share, up from $7.30 to $7.50.
Despite the beat, shares fell after the report because management flagged real 2027 headwinds. CVS Caremark faces pressure from the 340B drug discount program, where manufacturer restrictions and generic conversions squeeze margins. Caremark membership is also expected to decline next year as some health plan clients exit during a shift toward net-cost pricing.
That transition aims to satisfy regulators long term, but it creates near-term uncertainty. If CVS stock is going to hold its recent gains, management needs concrete offsets well before year end.
CEO David Joyner struck a confident tone anyway. “We generated adjusted operating income of $5.2 billion and adjusted earnings per share of $2.58,” Joyner told analysts, crediting a “deliberate enterprise-wide focus on building trust.”
Break down CVS’s earnings power using 5 years of forecasts (It’s free) >>>
Is CVS Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue Growth (CAGR): 3.6%
- Operating Margins: 4.2%
- P/E Multiple: 10.1x
Based on these inputs, the model estimates a target price of $107, implying 12.9% total upside from the current share price and a 5.4% annualized return over the next 2.3 years.
CVS trades at a single-digit forward multiple, which usually signals either deep value or genuine concern about future earnings. Given the 2027 headwinds management just flagged, the market seems to lean toward the latter.
A 3.6% revenue growth assumption is modest for a company generating over $400 billion in sales, reflecting caution around Caremark’s membership losses. Operating margins near 4.2% remain thin, typical for a pharmacy-heavy model, and have also faced pressure from drug mix shifts.
The 10.1x forward multiple sits below CVS’s own historical range and well below UnitedHealth’s roughly 21x forward earnings. That gap suggests the market views CVS’s integrated model as riskier than a pure insurer right now.
Whether that discount closes depends on execution through 2027, particularly how well CVS offsets membership losses with GLP-1 growth.
Weigh CVS’s discount against its own history (Free with TIKR) >>>
The PBM Margin Squeeze: CVS vs. UnitedHealth and Cigna
CVS operates in a three-way PBM market alongside UnitedHealth (UNH) and Cigna (CI), and the comparison shows how compressed valuations have become sector-wide. UnitedHealth trades at roughly 21x forward earnings despite posting the group’s slowest revenue growth at 6.5% over the trailing 12 months, while CVS’s own trailing growth of 7.4% actually outpaces both rivals. Cigna trades at a cheaper 9.5x forward multiple as Express Scripts overtook CVS Caremark as the largest PBM by volume in 2025.
That reshuffling matters for CVS’s position. Cigna is rolling out a rebate-free pharmacy model that could pressure CVS to accelerate its own transition, while UnitedHealth’s Optum keeps expanding its clinic footprint against CVS’s Oak Street Health business. All three face the same 340B scrutiny, but CVS’s Caremark scale gives it more room to absorb losses than smaller players. Against that backdrop, CVS’s 10.1x multiple looks closer to Cigna’s discount than UnitedHealth’s premium.
What’s Driving CVS Stock Going Forward?
CVS’s near-term catalysts center on proving it can offset 2027’s structural headwinds. Management plans to detail specific 340B and membership impacts on the Q3 call, giving investors real numbers behind August’s cautious commentary.
GLP-1 weight loss drugs represent a genuine growth lever. CVS is capturing volume through funded Caremark and Aetna programs and the growing cash-pay market, which could offset some membership attrition if execution holds. A proposed FTC settlement on insulin pricing could also reduce regulatory overhang heading into next year.
Oak Street Health, CVS’s primary care business, grew revenue nearly 23% last quarter and remains a long-term growth engine even as the core PBM faces pressure. CVS reaffirmed confidence in its mid-teens adjusted EPS compound growth target through 2028, but that target now depends more on execution than tailwinds.
Map CVS’s path through 2027 (Free with TIKR) >>>
Should You Invest in CVS Health?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze CVS stock on TIKR Free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
